BioSpace News Archive

This transaction increases BioIVT’s global network for collecting high-quality, disease-state biospecimens and extends its capabilities to deliver fresh biospecimens and produce cell products for drug and diagnostic development.

CSL Seqirus, a business of CSL Limited (ASX:CSL), today announced new data highlighting the significant burden influenza places on hospitals and healthcare resource use, as well as on more vulnerable populations such as children.

CSL Seqirus, a business of CSL Limited (ASX:CSL), today announced new data from four real-world studies showing the impact that cell-based and adjuvanted influenza vaccines can have in reducing the burden of seasonal influenza on hospitals and health systems.

Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces the participation of Sensorion’s management in various upcoming investor conferences.

CatalYm announced that it has received Investigational New Drug clearance from the US FDA to expand its ongoing Phase 2 clinical program to include clinical trial centers in the U.S. The ongoing GDFATHER-2 program is evaluating the company’s lead candidate, Visugromab in combination with an anti-PD1 antibody in patients with advanced solid tumors that are relapsed/refractory to prior anti-PD1/-PD-L1 treatment.

Atamyo Therapeutics announced the dosing with ATA-100 of a first patient in a phase 1/2 clinical study in FRKP-related limb-girdle muscular dystrophy type 2I/R9.

UCB today announced that it has been awarded the prestigious LEED (Leadership in Energy and Environmental Design) Certification at the Gold level by the U.S. Green Building Council (USGBC) and WELL Certification at the Platinum level by the International WELL Building Institute.

Anebulo Pharmaceuticals, Inc. today announced that it has agreed to sell an aggregate of 2,264,650 common shares and accompanying warrants to purchase up to 2,264,650 shares of common stock.

PerkinElmer, Inc. , (NYSE: PKI), a global leader committed to innovating for a healthier world, today launched the Cellaca ® PLX Image Cytometry System, a first-of-its-kind benchtop platform that enables researchers to assess multiple Critical Quality Attributes (CQAs) of cell samples in a single automated workflow.

Theratechnologies Inc. today announced that it will report financial results for its third quarter of fiscal 2022 ended August 31, on Thursday, October 13, 2022.